摘要
In April 2019, Serrano-del Valle and colleagues summarized the current applications of immunotherapy in the plasma cell malignancy multiple myeloma (MM) (Serrano-Del Valle et al., 2019).The authors moreover highlighted the connection of endoplasmic reticulum (ER) stress and the occurrence of immunogenic cell death (ICD).ICD is able to provoke potent adaptive immune responses and is based on the release of danger-associated molecular patterns (DAMPs) in a spatiotemporal manner (Garg et al., 2015).Interestingly, ER-stress pathways are important for DAMP exposure, including ecto-calreticulin, HMGB1, and ATP (Serrano-Del Valle et al., 2019).MM cells display enhanced ER-stress, hence making them dependent on ER-stress-related survival pathways.Compounds that target these survival pathways or that induce excessive amounts of ERstress are very effective in targeting MM cells.Therefore, it is tempting to speculate that ICD is an important mode of action of standard-of-care treatment.To assess the occurrence of ICD in vivo, a vaccination assay can be performed in which dying tumor cells are used as a vaccine in mice (Kepp et al., 2014).In case bona fide ICD occurs, mice will be protected against a challenge with living tumor cells.We were the first to perform this vaccination assay using the syngeneic immunocompetent 5T33MM model (De Beck et al., 2018).The vaccine consisted of 5T33vt cells treated with bortezomib, melphalan, a DNA methyltransferase inhibitor (decitabine), a histone deacetylase inhibitor (quisinostat) or the combination of decitabine and quisinostat.We also used a well-known chemotherapeutic compound that induces ICD in solid cancers, i.e., mitoxantrone (Emeagi et al., 2012;Bezu et al., 2015).None of these treatments gave rise to a vaccine that provided 100% protection against MM outgrowth upon a subsequent challenge with living MM cells.This indicates that ICD did not occur in this model.When looking at the concept of ICD, it is important to note that bona fide ICD can only occur when tumor cells can expose the necessary DAMPs in response to treatment and when the recruited immune cells are not compromised in their function.However, when tumor cells cannot present all DAMPs, express tolerogenic molecules, or when immune cells cannot react properly on the DAMPs, ICD becomes inefficient resulting in tolerogenic cell death (TCD) (Garg et al., 2016).The occurrence of ICD in MM is influenced by the balance of tolerogenic and immunogenic molecules and the